Concepedia
Statistics
Publications
9
Citations
635
H-Index
Active since
2001
Affiliations
National Cancer Institute(Current)
Naval Medical Center Portsmouth
Alexander T. Augusta Military Medical Center
Brooke Army Medical Center
Madigan Army Medical Center
Ann Rutt is an author at National Cancer Institute specializing in pharmacology, medicine, and chemotherapy dose-limiting toxicity.
Publications per year
2001–2023
Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days
Jame Abraham, Manish Agrawal, Susan Bakke et al. · Journal of Clinical Oncology · 2003 · 136 citations
Medicine, Pharmacokinetics, Pharmacology +12
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma
Jame Abraham, Susan Bakke, Ann Rutt et al. · Cancer · 2002 · 120 citations
Medicine, Oncology, Pharmacology +15
A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Jame Abraham, Maureen Edgerly, Richard H. Wilson et al. · Clinical Cancer Research · 2009 · 117 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +10
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
Isagani Chico, Min H. Kang, Raymond C. Bergan et al. · Journal of Clinical Oncology · 2001 · 89 citations
Pharmacy, Pharmacokinetics, Pharmacology +16
A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
Sen Hong Zhuang, Manish Agrawal, Maureen Edgerly et al. · Cancer · 2005 · 81 citations · Full text
1–5 of 9